がん生検の市場規模、シェア、動向分析レポート：製品別、タイプ別、用途別、地域別、セグメント別予測、2024年～2030年

がん生検市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん生検市場規模は2030年までに516億1,000万米ドルに達し、2024年から2030年までのCAGRは8.11％を記録すると予測されています。

分子医学の進歩により、がんの分子特性解析のための新しい装置の開発が容易になった。その結果、リキッドバイオプシーの受容と承認の高まりが市場全体の成長の大きな原動力になると予測されています。

数多くの新興メーカーが、内視鏡ベースのがん生検を改善できる機器の開発に専念しています。例えば、2023年3月、スウェーデンのBiBBInstruments AB社は、EndoDrillというブランドでがん生検市場に確固たる地位を築いた。同社は、既存の生検器具に関連して、がん患者の迅速かつ正確な診断を可能にする生検器具を変更しました。さらに、コアニードルや軟性内視鏡生検に対応した生検器具を提供しています。このような新興国市場を開拓している企業は、がん生検器具のアクセシビリティを高めると予想されます。

腫瘍学に基づくゲノムデータ解析と個別化医療の分野は、リキッドバイオプシーの出現によって有利な展望を示すと予想されます。規制機関は、リキッドバイオプシーがもたらす大きな可能性により、これらの製品の商業化を積極的に支援し、臨床現場での利用を促進しています。リキッドバイオプシーは、様々な体液を通してがんの検出を容易にし、この技術の進歩により、診断目的のがん生体物質を得るための魅力的な非侵襲的アプローチとなっています。

リキッドバイオプシー分野は、バイオ医薬品製造やゲノムデータ解析に携わる企業の大規模な投資や戦略的努力によって、今後数年間で急速に拡大すると予測されています。新興企業は、QIAGEN Bioinformatics、Fabric Genomics、Agilent Technologies、SOPHiA Geneticsのような既存の業界参加企業とパートナーシップを結ぶことに強い傾向を示しています。このような共同研究の動向は、市場全体の成長をさらに押し上げると予想されます。

がん生検市場レポートハイライト

• 2023年、キットと消耗品が製品別で最大の市場シェアを占め、この優位性は予測期間を通じて持続すると予測されます。キットおよび消耗品の採用増加は、腫瘍生検からリキッド生検への顕著なシフトに起因します。
• 組織生検は依然として生検プロセスの基本であり、さまざまな診断用途で広く利用されています。さらに、腫瘍生検は主に個人レベルの診断と進行中の腫瘍治療の有効性のモニタリングに使用されています。
• 用途別では、乳がんが2023年の世界市場を独占し、予測期間中もそのリードを維持すると予想されます。開腹手術による生検は、そのような病態の診断において確立された正確性により、疑わしい乳房病変を有する患者を評価するための基準として依然として用いられています。その結果、このセグメントの収益は、乳房病変診断におけるその実証された有効性によって強化されています。
• 北米は、活動的な組織やがん財団が集中しているため、2023年に最大の収益シェアを占めました。米国の政府組織と民間がん財団の強力なネットワークは、この地域の収益創出能力に大きく貢献しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん生検市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• がん生検市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 がん生検市場：製品の推定・動向分析

• 世界のがん生検市場：製品ダッシュボード
• 世界のがん生検市場：製品変動分析
• 製品別、収益
• 機器
• キットと消耗品
• サービス

第5章 がん生検市場：タイプの推定・動向分析

• 世界のがん生検市場：タイプダッシュボード
• 世界のがん生検市場：タイプ変動分析
• タイプ別、収益
• 組織生検
• 液体生検
• その他

第6章 がん生検市場：用途の推定・動向分析

• 世界のがん生検市場：用途ダッシュボード
• 世界のがん生検市場：用途変動分析
• 用途別、収益別
• 乳がん
• 大腸がん
• 子宮頸がん
• 肺がん
• 前立腺がん
• 皮膚がん
• 血液がん
• 腎臓がん
• 肝臓がん
• 膵臓がん
• 卵巣がん
• その他

第7章 がん生検市場：タイプ、製品、用途、用途別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2023
  • QIAGEN
  • Illumina, Inc.
  • ANGLE plc
  • BD（Becton, Dickinson and Company）
  • Myriad Genetics, Inc.
  • Hologic, Inc.
  • Biocept, Inc.
  • Thermo Fisher Scientific, Inc.
  • Danaher
  • F. Hoffmann-La Roche Ltd.
  • Lucence Health Inc.
  • GRAIL, Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • Biodesix（Integrated Diagnostics）
  • Oncimmune
  • Epigenomics AG
  • HelioHealth（Laboratory for Advanced Medicine）
  • Genesystems, Inc.（Genesys Biolabs）
  • Chronix Biomedical, Inc.
  • Personal Genome Diagnostics Inc.
  • Natera, Inc.
  • Personalis Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 4 Global Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 5 Global Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 6 Global Cancer Biopsy Market, by Region, 2018 - 2030 (USD Billion)
• Table 7 North America Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
• Table 8 North America Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 9 North America Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 10 North America Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 11 U.S. Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 12 U.S. Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 13 U.S. Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 14 Canada Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 15 Canada Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 16 Canada Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 17 Mexico Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 18 Mexico Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 19 Mexico Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 20 Europe Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
• Table 21 Europe Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 22 Europe Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 23 Europe Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 24 Germany Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 25 Germany Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 26 Germany Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 27 UK Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 28 UK Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 29 UK Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 30 France Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 31 France Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 32 France Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 33 Italy Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 34 Italy Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 35 Italy Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 36 Spain Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 37 Spain Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 38 Spain Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 39 Denmark Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 40 Denmark Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 41 Denmark Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 42 Sweden Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 43 Sweden Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 44 Sweden Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 45 Norway Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 46 Norway Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 47 Norway Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 48 Asia Pacific Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
• Table 49 Asia Pacific Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 50 Asia Pacific Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 51 Asia Pacific Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 52 China Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 53 China Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 54 China Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 55 Japan Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 56 Japan Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 57 Japan Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 58 India Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 59 India Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 60 India Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 61 South Korea Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 62 South Korea Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 63 South Korea Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 64 Australia Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 65 Australia Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 66 Australia Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 67 Thailand Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 68 Thailand Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 69 Thailand Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 70 Latin America Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
• Table 71 Latin America Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 72 Latin America Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 73 Latin America Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 74 Brazil Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 75 Brazil Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 76 Brazil Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 77 Argentina Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 78 Argentina Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 79 Argentina Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 80 Middle East & Africa Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
• Table 81 Middle East & Africa Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 82 Middle East & Africa Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 83 Middle East & Africa Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 84 South Africa Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 85 South Africa Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 86 South Africa Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 87 Saudi Arabia Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 88 Saudi Arabia Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 89 Saudi Arabia Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 90 UAE Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 91 UAE Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 92 UAE Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
• Table 93 Kuwait Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
• Table 94 Kuwait Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
• Table 95 Kuwait Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Cancer Biopsy Market Segmentation
• Fig. 8 Market Snapshot, 2023
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Global Cancer Biopsy Market: Product & Services Movement Analysis
• Fig. 16 Global Cancer Biopsy Market, for Instruments, 2018 - 2030 (USD Billion)
• Fig. 17 Global Cancer Biopsy Market, for Kits and Consumables, 2018 - 2030 (USD Billion)
• Fig. 18 Global Cancer Biopsy Market, for Services, 2018 - 2030 (USD Billion)
• Fig. 19 Global Cancer Biopsy Market: Type Movement Analysis
• Fig. 20 Global Cancer Biopsy Market, for Tissue Biopsies, 2018 - 2030 (USD Billion)
• Fig. 21 Global Cancer Biopsy Market, for Liquid Biopsies, 2018 - 2030 (USD Billion)
• Fig. 22 Global Cancer Biopsy Market, for Other, 2018 - 2030 (USD Billion)
• Fig. 23 Global Cancer Biopsy Market: Application Movement Analysis
• Fig. 24 Global Cancer Biopsy Market, for Breast Cancer, 2018 - 2030 (USD Billion)
• Fig. 25 Global Cancer Biopsy Market, for Colorectal Cancer, 2018 - 2030 (USD Billion)
• Fig. 26 Global Cancer Biopsy Market, for Cervical Cancer, 2018 - 2030 (USD Billion)
• Fig. 27 Global Cancer Biopsy Market, for Lung Cancer, 2018 - 2030 (USD Billion)
• Fig. 28 Global Cancer Biopsy Market, for Prostate Cancer, 2018 - 2030 (USD Billion)
• Fig. 29 Global Cancer Biopsy Market, for Skin Cancer, 2018 - 2030 (USD Billion)
• Fig. 30 Global Cancer Biopsy Market, for Blood Cancer, 2018 - 2030 (USD Billion)
• Fig. 31 Global Cancer Biopsy Market, for Kidney Cancer, 2018 - 2030 (USD Billion)
• Fig. 32 Global Cancer Biopsy Market, for Liver Cancer, 2018 - 2030 (USD Billion)
• Fig. 33 Global Cancer Biopsy Market, for Pancreatic Cancer, 2018 - 2030 (USD Billion)
• Fig. 34 Global Cancer Biopsy Market, for Ovarian Cancer, 2018 - 2030 (USD Billion)
• Fig. 35 Global Cancer Biopsy Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 36 Regional Marketplace: Key Takeaways
• Fig. 37 Regional Outlook, 2023 & 2030
• Fig. 38 Global Cancer Biopsy Market: Region Movement Analysis
• Fig. 39 North America Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 40 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 41 Canada Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 42 Mexico Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 43 Europe Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 44 Germany Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 45 UK Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 46 France Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 47 Italy Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 48 Spain Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 49 Denmark Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 50 Sweden Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 51 Norway Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 52 Asia Pacific Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 53 Japan Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 54 China Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 55 India Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 56 Australia Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 57 South Korea Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 58 Thailand Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 59 Latin America Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 60 Brazil Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 61 Argentina Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 62 Middle East and Africa Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 63 South Africa Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 64 Saudi Arabia Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 65 UAE Cancer Biopsy Market, 2018 - 2030 (USD Billion)
• Fig. 66 Kuwait Cancer Biopsy Market, 2018 - 2030 (USD Billion)

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

• In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
• Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
• In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
• North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and type outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advent of liquid biopsy
    • 3.2.1.2. Transition of novel oncology diagnostics from bench to clinics
    • 3.2.1.3. Advancements in quality and payment pertaining to genetic cancer tests
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risks associated with biopsy procedures
    • 3.2.2.2. Technical and clinical challenges
• 3.3. Cancer Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cancer Biopsy Market: Product Estimates & Trend Analysis

• 4.1. Global Cancer Biopsy Market: Product Dashboard
• 4.2. Global Cancer Biopsy Market: Product Movement Analysis
• 4.3. Global Cancer Biopsy Market by Product, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Kits and Consumables
  • 4.5.1. Kits and consumables market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Cancer Biopsy Market: Type Estimates & Trend Analysis

• 5.1. Global Cancer Biopsy Market: Type Dashboard
• 5.2. Global Cancer Biopsy Market: Type Movement Analysis
• 5.3. Global Cancer Biopsy Market by Type, Revenue
• 5.4. Tissue Biopsies
  • 5.4.1. Tissue biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Needle Biopsies
  • 5.4.3. Needle biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Fine Needle Aspiration (FNA)
    • 5.4.4.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Core Needle Biopsy (CNB)
    • 5.4.5.1. Core Needle Biopsy (CNB) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. Surgical Biopsies
  • 5.4.7. Surgical biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Liquid Biopsies
  • 5.5.1. Liquid biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Cancer Biopsy Market: Application Estimates & Trend Analysis

• 6.1. Global Cancer Biopsy Market: Application Dashboard
• 6.2. Global Cancer Biopsy Market: Application Movement Analysis
• 6.3. Global Cancer Biopsy Market by Application, Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Colorectal Cancer
  • 6.5.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Cervical Cancer
  • 6.6.1. Cervical cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Lung Cancer
  • 6.7.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Prostate Cancer
  • 6.8.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. Skin Cancer
  • 6.9.1. Skin cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.10. Blood Cancer
  • 6.10.1. Blood cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.11. Kidney Cancer
  • 6.11.1. Kidney cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.12. Liver Cancer
  • 6.12.1. Liver cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.13. Pancreatic Cancer
  • 6.13.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.14. Ovarian Cancer
  • 6.14.1. Ovarian cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.15. Others
  • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. QIAGEN
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Illumina, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. ANGLE plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BD (Becton, Dickinson and Company)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Myriad Genetics, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Hologic, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Biocept, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Thermo Fisher Scientific, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danaher
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. F. Hoffmann-La Roche Ltd.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Lucence Health Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. GRAIL, Inc.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives
  • 8.3.16. Guardant Health Inc.
    • 8.3.16.1. Company overview
    • 8.3.16.2. Financial performance
    • 8.3.16.3. Product benchmarking
    • 8.3.16.4. Strategic initiatives
  • 8.3.17. Exact Sciences Corporation
    • 8.3.17.1. Company overview
    • 8.3.17.2. Financial performance
    • 8.3.17.3. Product benchmarking
    • 8.3.17.4. Strategic initiatives
  • 8.3.18. Freenome Holdings, Inc.
    • 8.3.18.1. Company overview
    • 8.3.18.2. Financial performance
    • 8.3.18.3. Product benchmarking
    • 8.3.18.4. Strategic initiatives
  • 8.3.19. Biodesix (Integrated Diagnostics)
    • 8.3.19.1. Company overview
    • 8.3.19.2. Financial performance
    • 8.3.19.3. Product benchmarking
    • 8.3.19.4. Strategic initiatives
  • 8.3.20. Oncimmune
    • 8.3.20.1. Company overview
    • 8.3.20.2. Financial performance
    • 8.3.20.3. Product benchmarking
    • 8.3.20.4. Strategic initiatives
  • 8.3.21. Epigenomics AG
    • 8.3.21.1. Company overview
    • 8.3.21.2. Financial performance
    • 8.3.21.3. Product benchmarking
    • 8.3.21.4. Strategic initiatives
  • 8.3.22. HelioHealth (Laboratory for Advanced Medicine)
    • 8.3.22.1. Company overview
    • 8.3.22.2. Financial performance
    • 8.3.22.3. Product benchmarking
    • 8.3.22.4. Strategic initiatives
  • 8.3.23. Genesystems, Inc. (Genesys Biolabs)
    • 8.3.23.1. Company overview
    • 8.3.23.2. Financial performance
    • 8.3.23.3. Product benchmarking
    • 8.3.23.4. Strategic initiatives
  • 8.3.24. Chronix Biomedical, Inc.
    • 8.3.24.1. Company overview
    • 8.3.24.2. Financial performance
    • 8.3.24.3. Product benchmarking
    • 8.3.24.4. Strategic initiatives
  • 8.3.25. Personal Genome Diagnostics Inc.
    • 8.3.25.1. Company overview
    • 8.3.25.2. Financial performance
    • 8.3.25.3. Product benchmarking
    • 8.3.25.4. Strategic initiatives
  • 8.3.26. Natera, Inc.
    • 8.3.26.1. Company overview
    • 8.3.26.2. Financial performance
    • 8.3.26.3. Product benchmarking
    • 8.3.26.4. Strategic initiatives
  • 8.3.27. Personalis Inc.
    • 8.3.27.1. Company overview
    • 8.3.27.2. Financial performance
    • 8.3.27.3. Product benchmarking
    • 8.3.27.4. Strategic initiatives